COMMUNIQUÉS West-GlobeNewswire

ADMA Biologics Reports Third Quarter 2018 Financial Results
08/11/2018
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, [...]
Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities
08/11/2018
BEVERLY, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update highlighting business [...]
Radient Technologies Inc. Announces AGM Results and Completion of Shares for Debt Transaction
08/11/2018
EDMONTON, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) today announces that all resolutions were passed by the requisite majority at its annual [...]
Extendicare Announces 2018 Third Quarter Results
08/11/2018
MARKHAM, Ontario, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and nine months ended September 30, 2018. Results are presented in [...]
Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
08/11/2018
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs [...]
Merus sera présente à la Jefferies 2018 London Healthcare Conference
08/11/2018
UTRECHT, Pays-Bas, 08 nov. 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics®), a [...]
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
08/11/2018
- 50/50 joint venture with investor syndicate led by Vivo Capital – - Expands global reach for TransCon products – COPENHAGEN, Denmark, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a [...]
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
08/11/2018
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is pleased to announce [...]
Intellia Therapeutics to Present at November Healthcare Investor Conferences
08/11/2018
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
08/11/2018
Company Executing on Lead Programs CPI-1205 and CPI-0610 Expects to Evaluate Proof of Concept for Both Programs in Mid-2019 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc., ( [...]
Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors
08/11/2018
SOUTH SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today [...]
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
08/11/2018
Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia ® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017 Approximately 47,500 Auryxia [...]
Tyme, Inc. to Present at the Stifel 2018 Healthcare Conference on November 13th
08/11/2018
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors, today announced that [...]
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
08/11/2018
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger [...]
Chembio Diagnostics Reports Third Quarter 2018 Financial Results
08/11/2018
MEDFORD, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the third [...]
Globus Medical Reports Third Quarter 2018 Results
08/11/2018
AUDUBON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the third quarter ended September 30, 2018. [...]
AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
08/11/2018
Reported positive top-line data from an interim analysis of its ongoing Phase 2a proof-of-concept clinical trial of etokimab in severe eosinophilic asthma Initiated Phase 2 ECLIPSE trial of etokimab in chronic [...]
Terra Tech Corp Reports Financial Results for the Third Quarter of 2018
08/11/2018
IRVINE, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Terra Tech Corp. (OTCQX: TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced its Third Quarter financial [...]
Dentsply Sirona Reports Third Quarter 2018 Results; Announces Restructuring Plan to Drive Value-Creation
08/11/2018
Reported Q3 revenues of $928.4 million, down 8.0% compared to prior year; constant currency decline 1 of 5.9% Q3 2018 GAAP EPS of $0.13 vs. $0.39 in Q3 2017. Q3 2018 Non-GAAP EPS of $0.38 compared with Non-GAAP EPS of $ [...]

Pages